PDF Cover

Macitentan Market

The market for Macitentan was estimated at $618 million in 2024; it is anticipated to increase to $944 million by 2030, with projections indicating growth to around $1.34 billion by 2035.

Report ID:DS1802328
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Macitentan
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Macitentan Market Outlook

Revenue, 2024

$618M

Forecast, 2034

$1.25B

CAGR, 2025 - 2034

7.3%

The Macitentan industry revenue is expected to be around $663.5 million in 2025 and expected to showcase growth with 7.3% CAGR between 2025 and 2034. The significant rise in the Macitentan markets growth can be linked to key factors at play here. One of the reasons is the increasing worldwide occurrence of Pulmonary Arterial Hypertension (PAH) which holds a pivotal position in this scenario. Moreover the growing need for Macitentan. An endothelin receptor antagonist predominantly employed in treating PAH. Highlights its importance. Progressive developments in the management of PAH have also heightened Macitentans significance in the realm of healthcare. This underscores its role, in combating this challenging condition effectively.

Macitentan, also known as Opsumit, is well known for its effectiveness in decreasing illness and death rates in patients with PAH ​​placing it ahead of other similar medications on the market. The unique ability of this treatment to block endothelin receptors and enhance heart function while extending life expectancy has made it a valuable component of guidelines for treating PAH and enhancing its potential in other medical fields such, as oncology highlights the diverse power and versatility of this medication.

Macitentan market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Macitentan Market Outlook

Market Key Insights

  • The Macitentan market is projected to grow from $618.4 million in 2024 to $1.25 billion in 2034. This represents a CAGR of 7.3%, reflecting rising demand across Pulmonary Arterial Hypertension, Connective Tissue Disease-PAH, and Congenital Heart Disease-PAH.

  • Actelion Pharmaceuticals Ltd, Johnson & Johnson, Zydus Cadila are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Macitentan market and are expected to observe the growth CAGR of 4.7% to 7.0% between 2024 and 2030.

  • Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 8.4% to 10.1%.

  • Transition like Emergence of Personalized Medicine is expected to add $31 million to the Macitentan market growth by 2030.

  • The Macitentan market is set to add $633 million between 2024 and 2034, with manufacturer targeting key segments projected to gain a larger market share.

  • With

    rising incidence of pulmonary arterial hypertension, and

    Increasing Pharmaceutical Randamp;D Activities, Macitentan market to expand 102% between 2024 and 2034.

macitentan market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Macitentan - Country Share Analysis

Opportunities in the Macitentan

The collaboration between pharmaceutical companies and technology firms has also the potential to lead to drug delivery methods, for Macitentan enabling the creation of advanced medication distribution systems that improve patient adherence and treatment outcomes.

Growth Opportunities in North America and Europe

In North America's healthcare landscape and research institutions are delving deeply into exploring the benefits of Macitentan drug treatment for Pulmonary Arterial Hypertension . The market is expanding due to robust regulatory measures improving drug approvals and ongoing clinical trials focused specificallyon PAH therapies. In this environment major players in the market are heavily investing in collaborations and cutting edge research to strengthen their position, in the industry. The region also experiences a frequency of related conditions which has led to an increased need for effective treatments such as Macitentan, for pulmonary arterial hypertension consequently fueling the expansion of the market.
The Macitentan market shows promising growth opportunities due to the increasing number of diseases requiring advanced treatments in the region. The presence of healthcare facilities and substantial investments in healthcare contribute to the business prospects of Macitentan in this region. Competition is intense in the region due to changes in the drug market after the expiration of key drug patents. Moreover the growing awareness about enhancing the quality of life for patients plays a role in encouraging more widespread use of drugs like Macitentan in everyday medical practices, across Europe.

Market Dynamics and Supply Chain

01

Driver: Increasing Prevalence of Pulmonary Arterial Hypertension and Growing Adoption of Combination Therapies

One major driver for macitentan is also the increasing prevalence of pulmonary arterial hypertension globally, fueled by aging populations, better diagnostic awareness, and expanded screening in at-risk groups such as connective tissue disease and congenital heart disease patients. As more individuals receive PAH diagnoses, demand for effective endothelin receptor antagonists like macitentan rises. A related growth factor is also the trend toward combination therapy regimens in PAH management. Clinicians increasingly prescribe macitentan alongside phosphodiesterase-5 inhibitors and prostacyclin analogs to enhance pulmonary vasodilation, improve hemodynamics, and reduce clinical worsening events. This multi-modal approach aligns with precision cardiopulmonary care and is also supported by treatment guidelines that emphasize aggressive, early intervention to optimize exercise capacity and survival. The synergy of broader disease awareness and expanded therapeutic protocols is also driving uptake of macitentan across specialty practices, boosting market penetration in both first-line and add-on therapy settings while reinforcing its role in long-term pulmonary vascular disease management.
A key niche driver for macitentan is also innovation in endothelin receptor antagonist formulations that improve safety, tolerability, and patient adherence. Macitentan’s once-daily oral dosing and balanced ETA/ETB blockade offer clinical advantages over older agents with more frequent dosing or unfavorable side effect profiles. This trend toward optimized pharmacokinetics and improved side effect management supports broader clinician confidence and patient compliance in chronic PAH care. As cardiology and pulmonary specialists emphasize quality-of-life outcomes, formulations that reduce hepatotoxicity risk while sustaining pulmonary vascular benefits are also increasingly preferred, strengthening macitentan’s competitive positioning and supporting sustained market growth in niche pulmonary hypertension segments.
02

Restraint: High Treatment Cost and Limited Reimbursement Access Restrict Patient Uptake

A significant restraint for macitentan is the high cost of therapy and inconsistent reimbursement coverage, which limits accessibility and dampens market expansion. As a specialty cardiopulmonary medication for pulmonary arterial hypertension, macitentan often carries a premium price compared to older endothelin receptor antagonists. Many insurers require step therapy or restrictive prior authorizations, delaying access or shifting patients to lower-cost alternatives. In markets with constrained healthcare budgets, patients may face high out-of-pocket costs, reducing initiation rates. This economic barrier affects demand patterns and revenue growth, particularly in emerging economies where insurance penetration for rare disease therapies remains low, and cost concerns drive prescribers toward generics or alternative regimens.
03

Opportunity: Focusing on Evolving Consumer Needs in Emerging Markets and Leveraging Untapped Segments

By identifying up and coming markets as sources of growth potentiality for Macitentan they can leverage the developing healthcare systems and increasing consumer knowledge about PAE to their advantage. Countries such as India China and Brazil offer possibilities for the advancement of Macitentan, in the market.
Macitentan shows promise for growth in medical fields beyond its current use in treating pulmonary arterial hypertension . Exploring the treatments effectiveness for uncommon lung diseases could open up new opportunities for Macitentan to reach a broader audience, in the market.
04

Challenge: Safety Profile Concerns and Competitive Therapeutic Alternatives Limiting Market Share

Another important restraint is safety profile concerns and competition from alternative PAH therapies, which can limit macitentan’s market share. Endothelin receptor antagonists require liver monitoring due to potential hepatotoxicity, and some clinicians may prefer drugs with better documented long-term safety or fewer lab monitoring requirements. At the same time, competitive drugs such as phosphodiesterase-5 inhibitors and prostacyclin analogs with established usage patterns offer effective PAH management, reducing reliance on macitentan as a first-line option. These clinical preference dynamics slow adoption despite macitentan’s efficacy, influencing prescribing behavior and overall demand in the PAH therapeutic landscape.

Supply Chain Landscape

1

Raw Material Acquisition

Johnson MattheyCambrex Corporation
2

API Formation

Actelion PharmaceuticalsJanssen Biotech
3

Product Manufacturing

Johnson & JohnsonNovartis
4

End Use

PAH treatmentSystemic Sclerosis treatment
Macitentan - Supply Chain

Use Cases of Macitentan in Pulmonary Arterial Hypertension & Congenital Heart Disease-PAH

Pulmonary Arterial Hypertension : In the treatment of pulmonary arterial hypertension, macitentan is used as an oral endothelin receptor antagonist that helps reduce pulmonary vascular resistance and slow disease progression. Cardiologists and pulmonologists prescribe macitentan tablets for adults diagnosed with WHO Group 1 PAH because it blocks endothelin-1 signaling, a potent vasoconstrictor involved in vascular remodeling. Its once-daily dosing and sustained receptor blockade improve exercise capacity and delay clinical worsening. In clinical practice, macitentan is often incorporated into combination therapy regimens with phosphodiesterase-5 inhibitors or prostacyclin analogs, enhancing symptom control, reducing hospitalizations, and improving quality of life for PAH patients.
Connective Tissue Disease-PAH : For patients with connective tissue disease-associated PAH (CTD-PAH), including systemic sclerosis and lupus, macitentan provides targeted pulmonary vasodilation and vascular protection. Specialists in rheumatology and cardiopulmonary care favor macitentan because connective tissue disorders often exacerbate pulmonary vascular dysfunction, making effective endothelin blockade critical. The drug’s pharmacological profile helps reduce the risk of clinical worsening and supports improved hemodynamics in a population with complex comorbidities. Its role in combination therapy is particularly valuable in CTD-PAH, where aggressive management is essential to counteract progressive vessel narrowing and improve exercise tolerance and long-term outcomes.
Congenital Heart Disease-PAH : In congenital heart disease-associated PAH (CHD-PAH), macitentan is prescribed to manage elevated pulmonary pressures that arise from congenital cardiac defects and abnormal circulatory dynamics. Pediatric and adult congenital cardiologists often use macitentan to delay symptomatic progression and reduce right heart strain when surgical correction is not possible or as adjunctive therapy post-repair. Oral administration and a favorable safety profile make it suitable for long-term management. By blocking endothelin receptors, macitentan helps improve blood flow through the lungs, alleviates dyspnea, and can contribute to enhanced exercise capacity and reduced hospitalization rates in CHD-PAH patients.

Recent Developments

Recent developments for macitentan highlight its strengthening role in pulmonary arterial hypertension management as clinicians adopt combination therapy protocols that pair endothelin receptor antagonists with PDE-5 inhibitors and prostacyclin analogs for better hemodynamic outcomes. A key trend is the emphasis on personalized PAH care and long-term disease management, supported by real-world evidence and patient monitoring tools that improve adherence and quality of life. These shifts are expanding macitentan’s clinical use and reinforcing its strategic positioning in cardiopulmonary therapeutic portfolios.

December 2024 : Actelions Pharmaceuticals unveiled an upgraded version of Macitentan that provides improved dosage management options. This update aims to offer flexibility, for doctors and enhance treatment customization for patients.
October 2024 : On World Pulmonary Hypertension Day Pfizer Inc ramped up Macitentan production to keep up with the increasing demand.
July 2024 : Johnson & Johnson has disclosed a long term partnership, with Eli Lilly to investigate uses of Macitentan in the realm of personalized medicine.

Impact of Industry Transitions on the Macitentan Market

As a core segment of the Pharmaceutical industry, the Macitentan market develops in line with broader industry shifts. Over recent years, transitions such as Emergence of Personalized Medicine and Advancements in Drug Delivery Systems have redefined priorities across the Pharmaceutical sector, influencing how the Macitentan market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Emergence of Personalized Medicine

The field of medicine has been experiencing changes due to the rise of personalized treatments like Macitentan in managing Pulmonary Arterial Hypertension . Through advancements in genomics and proteomics techniques healthcare professionals have enhanced the effectiveness of Macitentan therapy leading to results for patients and increased drug efficiency. This shift has driven up the demand for Macitentan. Solidified its reputation as an effective solution, in managing PAHP.
02

Advancements in Drug Delivery Systems

The field has also seen progress in drug delivery systems that have enhanced the effectiveness of drugs such as Macitentan. Innovative delivery techniques have minimized side effects and made it easier for patients to follow their treatment plans by simplifying the way medication is taken. A clear example of this progress is the change in how Macitentan is administered. Moving from oral methods to modified release systems. This shift has led to an improvement in how patients feel during treatment and their overall outcomes solidifying Macitentans position, in the field.